p53蛋白、雌激素受体、孕激素受体在非小细胞肺癌中的表达及临床意义

目的 检测非小细胞肺癌（ＮＳＣＬＣ）中ｐ５３蛋白、雌激素受体（ＥＲ）和孕激素受体（ＰＲ）表达与临床病理和预后的相关性。方法 应用免疫组织化学ＳＰ法检测１４７例ＮＳＣＬＣ癌组织标本中ｐ５３、ＥＲ、ＰＲ的表达。结果 ｐ５３蛋白总阳性率为６１．２％（９０／１４７）,鳞癌、腺癌、鳞腺癌、大细胞癌阳性率分别为６３．５％（４０／６３）、５７．６％（３３／６６）、６６．７％（１０／１４）、５０％（２／４）。腺癌

Expression and clinical significance of p53 protein , estrogen and progesterone receptors in non-small cell lung cancer

Objective To investigate the relationships between expression of tumor suppressor gene p53 protein, estrogen receptor (ER), progesterone receptor (PR) and clinicopathology and prognosis in human non small cell lung cancer (NSCLC). Methods Expression of p53 protein, ER and PR in 147 NSCLC specimen was detected by SP immunohistochemistry method. Results Overall, 61.2%(90/147) tumor tissues had positive p53 staining. The positive rate of p53 expression in squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma and large cell carcinoma was 63.5%(40/63), 57.6%(38/66), 66.7%(10/14), and 50%(2/4) respectively. The overexpression of p53 protein was associated with the prognosis of patients with adenocarcinoma, the positive rate of p53 expression of patients who survived for less than 3 years was 75%, which was significantly higher than 44.7% of patients who survived for more than 3 years(P<0.025). For ER and PR, the overall positive rate was 49.7%(73/147) and 76.9%(113/147) respectively. The positive rate of squamous cell carcinoma and adenocarcinoma was significantly higher than that of squamous cell carcinoma (P<0.005). Besides, expression area of ER and PR was often in the nucleus for squamous cell carcinoma and in the cytoplasma for adenocarcinoma (P<0.005). The 3 year survival rate in patients with cytoplasma staining for PR was significantly higher than that with nucleus staining (P<0.025). Conclusion The results suggest that overexpression of p53 in adenocarcinoma could be used as a prognostic factor for the patients. Detection of ER and PR may have a definite value in differentiating squamous cell carcinoma from adenocarcinoma. The prognosis is poor for PCR positive patients with nucleus staining.